Antitrust & Competition

Prof. Daniel Spulber's paper, Measuring the Private and Social Returns to R&D: Unintended Spillovers versus Technology Markets, was recently accepted by one of the most prestigious journals in economics, Journal of Political Economy.

Our featured expert, Jon Riddle, PhD, has worked as a professional economist for over 30 years. Dr. Riddle has provided expert opinions on a wide range of engagements including antitrust, health care, the pharmaceutical industry, and valuation and damages. In a recent case, Vega recently supported Dr. Riddle's profitability analysis of an infusion center. 

Prof. Daniel Spulber joined more than 150 public comments that were submitted to weigh in on the Draft Revised Statement on remedies for the infringement of standards-essential patents (or SEPs) that are subject to a RAND or F/RAND licensing commitment. 

Vega was retained by a group of major hedge funds as opt-out plaintiffs in several securities class actions to support Professor Lou Rossiter in analyzing issues related to pricing pressures and price fixing for certain drugs in the generic drug market.

Certain structural factors, when present in a given market, can facilitate anticompetitive behavior. In this article, we discuss ten factors that provide a useful starting point for contextualizing the competitive environment of a given market and providing a general framework within which to evaluate the specific data related to that market. 

This brochure highlights Vega's leading experts in antitrust litigation who can offer opinions on market definition and market power, market structure, pricing, profitability, and damages.

The regulatory framework for pharmaceuticals has evolved alongside this boom to facilitate the safe and affordable access to medicine as consumers increase their use of generics. This article reviews the historical development of the regulatory framework for generic pharmaceuticals in the U.S. and its economic impact, particularly in facilitating price competition.

President Biden's recent Executive Order announced a government-wide effort to fight overconcentration, monopolization, and unfair competition. To unpack the implications of this Order, Vega interviews Professor Daniel Spulber, who shares his insights about what businesses should be thinking about in light of this Order and how economic analysis can help evaluate its implications. 

Vega’s recently welcomed Dr. Daniel Spulber to our expert network. Dr. Spulber is an expert in antitrust, platforms and two-sided markets, intellectual property, technology and innovation, and industrial organization.

Our featured expert, Dr. Thomas Lys is is an expert in areas including accounting, corporate finance, corporate governance, real estate, and finance. Dr. Lys was recently supported by Vega to rebut plaintiffs’ damages calculations in seven cases brought against RMBS servicers and master servicers.

Our featured expert, Haim Kassa, is is an expert in the areas of investments and portfolio management and he is experienced in the design and testing of trading strategies using historical firm level data from the stock, bond, and option markets.

Our featured expert, Lou Rossiter, is an expert in health economics. He has served as an expert on numerous cases and most recently he has been retained with the support of the Vega team to provide an analysis of pricing pressure and price fixing in the generic drug market for certain drugs.

Vega discusses the threshold questions that will need to be answered in the antitrust analyses of the recent Facebook cases brought by the FTC and attorney general from numerous states.

The Vega team and experts provide analyses of the complete range of economic issues arising in antitrust litigation including market definition and market power, market structure, pricing, profitability, and damages. This publication highlights Vega's antitrust practice, explaining both our significant experience with antitrust engagements and some of the qualifications of our antitrust experts.